1. Home
  2. CCM vs CVRX Comparison

CCM vs CVRX Comparison

Compare CCM & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concord Medical Services Holdings Limited

CCM

Concord Medical Services Holdings Limited

N/A

Current Price

$3.59

Market Cap

21.3M

Sector

Health Care

ML Signal

N/A

Logo CVRx Inc.

CVRX

CVRx Inc.

HOLD

Current Price

$0.61

Market Cap

17.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCM
CVRX
Founded
1997
2000
Country
China
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3M
17.9M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
CCM
CVRX
Price
$3.59
$0.61
Analyst Decision
Hold
Analyst Count
0
7
Target Price
N/A
★ $1.65
AVG Volume (30 Days)
12.4K
★ 778.0K
Earning Date
11-27-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 23.02
EPS
★ N/A
N/A
Revenue
N/A
★ $56,651,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.66
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 10.45
52 Week Low
$2.79
$0.61
52 Week High
$6.80
$10.28

Technical Indicators

Market Signals
Indicator
CCM
CVRX
Relative Strength Index (RSI) 49.72 20.39
Support Level $3.28 N/A
Resistance Level $4.10 $1.55
Average True Range (ATR) 0.26 0.14
MACD -0.00 -0.04
Stochastic Oscillator 47.31 2.30

Price Performance

Historical Comparison
CCM
CVRX

About CCM Concord Medical Services Holdings Limited

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.

About CVRX CVRx Inc.

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Share on Social Networks: